Technical Trends Signal Renewed Momentum
The primary catalyst behind the upgrade is the marked improvement in Makers Laboratories’ technical grade, which shifted from mildly bullish to bullish. Key technical indicators underpinning this shift include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart and a mildly bullish MACD on the monthly chart. Additionally, Bollinger Bands have turned bullish on both weekly and monthly timeframes, signalling increased price momentum and volatility in the stock’s favour.
Daily moving averages have also aligned positively, reinforcing the short-term bullish sentiment. The Know Sure Thing (KST) indicator presents a mixed picture, with a bullish weekly reading but a bearish monthly trend, suggesting some caution in the longer term. Meanwhile, the Dow Theory remains mildly bullish across weekly and monthly periods, supporting the overall positive technical outlook.
This technical strength is reflected in the stock’s recent price action, with the share price rising 6.04% on the day to ₹158.00, after touching a high of ₹164.95. The stock remains below its 52-week high of ₹173.70 but has rebounded strongly from its 52-week low of ₹109.00.
Robust Quarterly Financial Performance
Makers Laboratories reported a strong set of results for Q3 FY25-26, which further bolstered investor confidence. The company posted Profit Before Tax excluding Other Income (PBT LESS OI) of ₹2.82 crores, representing a remarkable growth of 152.9% compared to the previous four-quarter average. Net sales reached a record high of ₹35.67 crores, while Profit Before Depreciation, Interest and Tax (PBDIT) also hit a quarterly peak at ₹4.16 crores.
These figures indicate a positive turnaround in operational efficiency and revenue generation, which contrasts favourably with the company’s longer-term financial trends. Despite this quarterly improvement, the company’s operating profits have declined at a compound annual growth rate (CAGR) of -15.78% over the past five years, highlighting ongoing challenges in sustaining growth.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Valuation Remains Elevated Despite Mixed Fundamentals
While the company’s recent financial results and technical indicators have improved, valuation metrics present a more nuanced picture. Makers Laboratories is classified as a micro-cap stock and currently trades at a Price to Book (P/B) ratio of 1.3, which is considered expensive relative to its peers in the Pharmaceuticals & Biotechnology sector. This premium valuation is notable given the company’s low average Return on Equity (ROE) of 2.20%, signalling limited profitability per unit of shareholder funds.
Moreover, the company’s ROE for the latest period stands at approximately zero, underscoring the challenges in generating consistent shareholder returns. Profitability has also been volatile, with profits falling by 82.7% over the past year despite the stock delivering a 17.78% return during the same period. This divergence between price performance and earnings highlights the market’s focus on technical momentum and recent quarterly improvements rather than long-term fundamental strength.
Long-Term Performance and Market Comparison
Over the last year, Makers Laboratories has outperformed the broader BSE500 index, delivering a 17.78% return compared to the index’s 4.49%. The stock’s performance over three years is even more impressive, with a cumulative return of 51.81% versus the BSE500’s 29.63%. However, over a five-year horizon, the stock has underperformed significantly, declining by 39.95% while the BSE500 gained 55.92%. Over ten years, the stock has delivered a 147.26% return, trailing the BSE500’s 214.35% gain.
This mixed long-term performance reflects the company’s cyclical challenges and the impact of fluctuating profitability on investor sentiment. The majority shareholding by promoters provides some stability, but the company’s weak long-term fundamental strength tempers enthusiasm for a stronger rating upgrade at this stage.
Technical and Financial Trends Combined to Justify Hold Rating
The upgrade to a Hold rating with a Mojo Score of 50.0 reflects a balanced assessment of Makers Laboratories’ prospects. The technical indicators have improved sufficiently to suggest a bullish near-term outlook, supported by strong quarterly earnings and positive sales momentum. However, the company’s expensive valuation, weak long-term profitability, and inconsistent financial trends justify a cautious stance.
Investors are advised to monitor the company’s ability to sustain profit growth and improve return metrics before considering a more aggressive Buy rating. The Hold rating signals that while the stock has stabilised and shows potential for further gains, risks remain due to valuation and fundamental concerns.
Holding Makers Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Rating Change Drivers
The upgrade from Sell to Hold on 8 April 2026 was driven by four key parameters:
- Quality: Improved quarterly profitability and record sales indicate better operational execution, though long-term fundamentals remain weak with low ROE and declining operating profits.
- Valuation: The stock trades at a premium P/B of 1.3 despite limited profitability, reflecting market optimism but also elevated risk.
- Financial Trend: Positive quarterly earnings growth of 152.9% in PBT LESS OI and highest-ever net sales and PBDIT support a short-term upward trend, offset by weak five-year profit CAGR.
- Technicals: Bullish weekly MACD, Bollinger Bands, moving averages, and Dow Theory readings underpin a stronger technical outlook, justifying the upgrade in technical grade from mildly bullish to bullish.
Overall, the Hold rating recognises the stock’s improved momentum and recent financial gains while acknowledging persistent valuation and fundamental challenges.
Investor Outlook
For investors, Makers Laboratories presents a cautiously optimistic opportunity. The stock’s recent outperformance relative to the Sensex and BSE500 indices, combined with technical strength, suggests potential for further gains in the near term. However, the company’s expensive valuation and weak long-term profitability metrics warrant a measured approach.
Monitoring upcoming quarterly results and any shifts in profitability trends will be critical to reassessing the stock’s investment potential. Until then, the Hold rating reflects a balanced view that favours stability over aggressive accumulation.
Market Context
In the broader Pharmaceuticals & Biotechnology sector, Makers Laboratories remains a micro-cap player with a niche presence. Its recent financial and technical improvements may attract attention from investors seeking small-cap turnaround stories, but the sector’s competitive dynamics and regulatory environment require vigilance.
As of 9 April 2026, the stock’s day range of ₹145.05 to ₹164.95 and a closing price of ₹158.00 indicate healthy intraday volatility, consistent with the bullish technical signals. The company’s ability to sustain this momentum will be key to future rating upgrades.
Conclusion
The upgrade of Makers Laboratories Ltd to a Hold rating by MarketsMOJO reflects a nuanced assessment of the company’s improved technical indicators and recent financial performance against a backdrop of challenging long-term fundamentals and valuation concerns. Investors should weigh the positive near-term signals against the risks inherent in the company’s profitability and valuation profile before making investment decisions.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
